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Abstract
: Cryptococcal meningitis is a leading cause of death inBackground
HIV-infected patients. International treatment guidelines recommend induction
therapy with amphotericin B and flucytosine. This antifungal combination is
most effective, but unfortunately flucytosine is expensive and unavailable
where the burden of disease is greatest. Where unavailable, guidelines
recommend treatment with amphotericin and fluconazole, but this is less
effective, with mortality rates of 40-50%. Faster rates of clearance of yeast from
cerebrospinal fluid (CSF) are associated with better outcomes - improving the
potency of antifungal therapy is likely to be an effective strategy to improve
survival. Tamoxifen, a selective estrogen receptor modulator used to treat
breast cancer, has anti-cryptococcal activity, appearing synergistic when
combined  with amphotericin, and fungicidal when combined within vitro 
fluconazole. It is concentrated in the brain and macrophages, off-patent, cheap
and widely available. We designed a randomized trial to deliver initial efficacy
and safety data for tamoxifen combined with amphotericin and fluconazole.
: A phase II, open-label, randomized (1:1) controlled trial of tamoxifenMethod
(300mg/day) combined with amphotericin (1mg/kg/day) and fluconazole
(800mg/day) for the first 2 weeks therapy for HIV infected or uninfected adults
with cryptococcal meningitis. The study recruits at Cho Ray Hospital and the
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam. The primary end
point is Early Fungicidal Activity (EFA-the rate of yeast clearance from CSF),
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 Any reports and responses or comments on
the article can be found at the end of the
article.
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam. The primary end
point is Early Fungicidal Activity (EFA-the rate of yeast clearance from CSF),
over the first two weeks of treatment. 50 patients will be recruited providing
≈80% and 90% power to detect a difference in the EFA of -0.11 or -0.13
log10CFU/ml/day, respectively.
 The results of the study will inform the decision to proceed to aDiscussion:
larger trial powered to mortality. The size of effect detectable has previously
been associated with reduced mortality from this devastating disease.
Particular side effects of interest include QT prolongation.
: Clinicaltrials.gov   (11/04/2017)Trial registration NCT03112031
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Background
Worldwide cryptococcal meningitis results in approximately 
625 000 deaths each year, most occurring within 3 months of 
diagnosis1. It is the leading cause of death in HIV patients in Asia 
and Africa affecting 3.2% of the HIV infected population per 
year1. Despite improvements in access to HIV care, the WHO 
estimates that even if 80% access to HIV treatment is achieved, 
there will be 6.5 million AIDS deaths p.a. by 20302. Thus, CM is 
likely to remain a significant health burden for the foreseeable 
future. While cryptococcal meningitis predominantly occurs 
in HIV infected patients, patients with other forms of immuno-
suppression are also affected3,4. Furthermore, in Viet Nam we 
see disease in apparently immunocompetent patients (N = 30 
each year at the Hospital for Tropical Diseases and Cho Ray 
Hospital) due to infection with Cryptococcus neoformans var. 
grubii, or, more rarely, C. gattii5.
There has been no major advance in the treatment of 
cryptococcal meningitis since the 1980’s, and the 90 day case 
fatality rate of cryptococcal meningitis remains unacceptably 
high, estimated at 55% in Asia and 70% in Africa1. The mainstays 
of induction therapy are drugs that are over 50 years old – ampho-
tericin B and flucytosine - although these are often poorly 
available where disease burden is highest6,7. While amphoter-
icin monotherapy is undoubtedly superior to fluconazole mono-
therapy, amphotericin combination therapy has only recently been 
shown to reduce mortality when compared with amphoter-
icin monotherapy in a randomized controlled trial in Vietnam8. 
In this study, in Vietnamese patients receiving gold standard 
treatment with amphotericin and flucytosine, the death rate at 
10 weeks and 6 months was 31% and 35%. This compared with 
33% and 46% in patients receiving amphotericin-fluconazole induc-
tion therapy (the current WHO guideline), and was significantly 
better than in patients receiving prolonged amphotericin mono-
therapy, where the death rates were 44% and 54% respectively8. 
A biological explanation for these better outcomes is that the 
amphotericin-flucytosine combination has increased sterilis-
ing power – it results in significantly more rapid clearance of 
yeast from cerebrospinal fluid than amphotericin monotherapy8. 
Consistent with this, the recent multi-country trial of adjunc-
tive dexamethasone in HIV associated cryptococcal meningitis 
has shown that this immune modulating treatment is associated 
with both reduced rates of clearance of yeast from CSF and 
worse clinical outcomes9.
Therefore, it seems that the rate of clearance of yeast from 
CSF is an important determinant of outcome from cryptococcal 
meningitis, and that improving the potency of antifungal therapy 
is likely to result in improved outcomes. Currently, flucytosine 
is unaffordable (costs of the most recently developed generic 
version are 15 000 USD/week), unavailable outside of Europe 
and the US, and has significant toxicities which can be difficult 
to manage in resource-poor settings. Therefore it is not currently 
a viable solution for patients where the vast burden of cryptococ-
cal disease occurs10. Instead, most patients worldwide are treated 
with amphotericin and fluconazole, as per WHO guidelines7. 
There is a pressing need to develop affordable, safe and 
practicable antifungal treatment regimens with greater sterilising 
power.
Current Treatment recommendations for CM
Successful treatment of CM depends upon effective anti-fungal 
therapy and successful management of complications, notably 
raised intracranial pressure. Antifungal treatment schedules 
for cryptococcal meningitis are not globally uniform but are 
affected by drug availability, costs and human resources. The 
Infectious Diseases Society of America convenes an interna-
tional panel to draw up treatment guidelines, most recently pub-
lished in 2010, and the WHO published guidelines aimed at 
management in resource-poor countries in 20116,7. These con-
form closely to the IDSA guidelines. Treatment generally 
consists of a period of induction therapy using high dose or 
combination antifungal therapy (usually for 2 weeks), followed 
by a period of consolidation therapy of 8 weeks with flucona-
zole. After this time, provided the patient has responded to treat-
ment, secondary prophylaxis using lower dose fluconazole is 
given to prevent disease relapse. It is generally considered safe to 
stop secondary prophylaxis if ARV therapy has resulted in sup-
pression of the plasma viral load and there has been immune 
reconstitution with recovery of the CD4 cell count to 
> 100 cells/uL for at least 6 months.
Consistent with the local practices and the WHO and IDSA 
guidelines, in this study all patients in the control arm will 
receive anti-fungal therapy consisting of amphotericin B 
(1mg/kg/day) combined with fluconazole 800mg/day for 
2 weeks, followed by fluconazole 800mg/day for a further 
8 weeks before switching to secondary prophylaxis6,7.
Rationale for a trial of tamoxifen
Current indications
Tamoxifen is an off-patent, widely available (licensed in Viet-
nam) and affordable selective oestrogen receptor modulator 
(SERM)11. Its initial indication was the treatment of breast can-
cer. There are many thousands of patient years’ experience of 
its use for this disease, where it has proved to be a safe, effec-
tive, and tolerable long term therapy. In addition to its effects 
against breast cancer, Tamoxifen, in higher doses, also has 
activity against other tumours including glioblastoma multiforme 
(GBM), desmoid tumours, lung and prostate cancer12–16.
Antifungal activity
In addition to its anti-cancer effects, Tamoxifen has been 
known to have activity against yeasts for several years, this first 
being identified against the model yeast Saccharomyces cerevisiae 
in 1989, and subsequently demonstrated against C. albicans17–19. 
In 2009 the first reports of activity against Cryptococcus 
neoformans were described20. The antifungal activity is of 
particular interest for the following reasons:
1.    In vitro, the combination of Tamoxifen with amphotericin 
is synergistic. This contrasts with the current most effec-
tive antifungal therapy – amphotericin and flucytosine 
– where the effects of each drug are simply additive11. 
A synergistic antifungal combination offers the 
opportunity to significantly improve CSF sterilisation 
and survival.
2.    In the mouse model of cryptococcosis, the combination 
of Tamoxifen with fluconazole is fungicidal11,21. No other 
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antifungal drug clearly has a fungicidal effect in vivo. 
The lack of fungicidal effect of conventional antifungal 
therapies may in part explain the slow cerebrospinal fluid 
(CSF) sterilisation and high death rates seen in cryptococ-
cal disease.
3.    Tamoxifen is concentrated in brain tissue22,23. This 
is the main site of cryptococcal disease. Current anti-
fungal drugs result in relatively rapid sterilisation of 
blood. However, they are much less effective at sterilis-
ing the central nervous system, with only approximately 
50% of patients having sterile cerebrospinal fluid 
after 2 weeks of conventional treatment8.
4.    Tamoxifen is concentrated in the macrophage 
phagosome11. In cryptococcal meningitis, yeast cells 
are engulfed by macrophages, but can survive and even 
reproduce within them. Unlike Tamoxifen, conven-
tional antifungal drugs cannot penetrate the macrophage 
phagosome, and this therefore represents a site where 
yeast cells may be relatively protected from treatment.
A drug combination with both fungicidal and synergistic 
activity, that is concentrated in the central nervous system and 
within macrophages, is an exciting prospect for cryptococcal 
disease, and has the potential to significantly improve outcomes.
Data from Vietnam
In vitro and in vivo experimental data concerning the effi-
cacy of Tamoxifen have been derived from experiments using 
the C. neoformans type strain H99. The Minimum Inhibitory 
Concentration (MIC) of Tamoxifen for H99 is 8-16ug/ml. 
To ensure applicability in Vietnam, we have determined the 
MIC of Tamoxifen for 30 clinical isolates of C. neoformans and 
C. gattii from Vietnamese patients with cryptococcal meningitis 
and confirmed it to be between 2-16ug/ml (unpublished data). 
We have also demonstrated that synergy with amphotericin B 
in vitro is seen for the majority of strains tested. Subsequently 
we have performed 3D chequerboard testing of the triple 
combination of amphotericin with fluconazole and Tamoxifen, 
and have shown that there is also synergy between the 3 drugs 
in triple combination, and moreover that a synergistic interac-
tion is also present for the few strains in which we failed to 
demonstrate synergy with the 2 drug combination. We have also 
demonstrated that there is no synergistic interaction in vitro 
when Tamoxifen is combined with flucytosine.
Mechanism of action
Tamoxifen is a selective estrogen modulating drug (SERM) 
that has both pro- and anti-estrogen effects. In breast cancer, 
it inhibits growth of (cancerous) breast tissue through modulat-
ing the expression of estrogen dependent genes and the subse-
quent expression of growth promoting signals. In Cryptococcus, 
Tamoxifen binds to calmodulin and calmodulin-like protein, 
preventing the activation of calcineurin11,20. The calmodulin- 
calcineurin pathway is key in intra-cellular signalling and 
in controlling the response of Cryptococcus to stress, such as 
that encountered following phagocytosis by macrophages.
Pharmacology and dosing
Tamoxifen has excellent dose-independent oral bioavailabil-
ity (approximately 100%) with minimal first-pass metabolism24. 
The half-life is 5–7 days. Tamoxifen’s SERM activity requires 
serum concentrations ~100 ng/mL. This is achieved with 
doses of 20 – 60 mg/day, and for breast cancer treatment at this 
dose is recommended for 5–10 years25. At these doses, brain tis-
sue concentrations are 40-100-fold higher (4-10 µg/mL), than in 
serum23. Higher doses of 240 – 500mg/day have been stud-
ied in clinical trials of treatment for CNS tumours, desmoid 
tumours and lung cancer and are well tolerated, safely achieving 
serum concentrations of 2-8ug/mL12–14,26–28. Treatment admin-
istration regimens at these doses vary: month-long cycles of 
300mg/day are given for desmoid tumours in children28; doses of 
120mg/m2 BID have been given for up to 1 year and well toler-
ated in patients with glioblastoma multiforme27. Such treatment 
regimens establish Tamoxifen serum concentrations around the 
C. neoformans MIC and, will achieve brain concentrations 
40-100-fold higher, suggesting levels sufficient to treat CM 
will be achieved using oral dosing in humans23. Moreover, 
uniquely compared with other antifungal drugs, Tamoxifen is 
further concentrated in macrophage phagosomes – an important 
site of C. neoformans replication11.
Adverse effects
Tamoxifen is a well-tolerated drug. Adverse effects must 
be considered in the context of the severity of the disease being 
treated. Survival rates for breast cancer, GBM and crypto-
coccal meningitis are illustrated in Table 1. The beneficial 
effects of Tamoxifen in women diagnosed with breast cancer 
are considered to considerably outweigh the potential adverse 
effects of Tamoxifen.
Table 1. Survival rates: breast cancer, glioblastoma and cryptococcal meningitis.
Condition Survival Metric Survival rate* Tamoxifen dose used
Breast Cancer 1 year survival 95% 20–40mg/day
Glioblastoma multiforme 2 year survival rate 66% 300mg/day
Small cell lung cancer 5 year survival rate 8 – 31% 300–500mg/day
Cryptococcal meningitis 6 month survival rate 45 – 55% Suggested 300mg/day
*Sources: http://www.cancerresearchuk.org/about-cancer/type, American Cancer Society, Beardsley  
et al., NEJM 2014, Park et al., 2009. Note, survival rates are overall survival rates for the condition stated, 
and not specifically for Tamoxifen containing regimens.
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Headaches, nausea and vomiting
Data from randomised controlled trials suggest that these 
symptoms are no more common than in patients receiving 
placebo29.
Hot flushes and impaired libido
These symptoms are likely mediated through oestrogen 
modulation, can occur acutely, and are reversible when treatment 
stops.
Pulmonary embolism, cataracts and endometrial 
cancer
Data from trials of prophylactic treatment for breast can-
cer suggest that long term use is associated with an increased 
risk of pulmonary embolism (Relative Risk (RR) = 3.01, 95% 
Confidence Interval (CI): 1.15 to 9.27), cataracts (RR = 1.13, 
95% CI: 1.00 to 1.28)and endometrial cancer (RR = 2.48, 95% 
CI: 1.27 to 4.92,30. However, the actual rate of these events is 
very low (0.75 per 1000 patient years, 25 per 1000 patient years 
and 2.2 per 1000 patient years respectively)29,30. Thromboembolic 
events occurred an average of 19 months after starting treatment, 
and none within the first 2 months30. The risk of these events 
with short course treatment is much lower. It is not considered 
worthwhile to screen for factor V Leiden prior to treatment 
with Tamoxifen unless there is a family or personal history of 
previous thromboembolic disease. The increased risk of 
endometrial cancer is likely due to chronic modulation of oestro-
gen, is related to duration of use, and clearly does not exist for 
male patients.
Teratogenicity
Tamoxifen is teratogenic and should not be taken by pregnant 
women. Fluconazole is also a teratogenic drug, and pregnant 
women are not eligible to enter this study. Women of child- 
bearing potential will be screened at study entry for pregnancy 
with a urine pregnancy test. All study participants will be advised 
to use barrier contraception until at least 3 months after study end.
Prolongation of the QT interval
Tamoxifen can result in prolongation of the QT interval of car-
diac depolarisation16,31. QT prolongation is a recognised side 
effect of a number of drugs including some antimicrobials, anti-
arrhythmic drugs and psychoactive drugs32. For some drugs, QT 
prolongation is associated with a risk of developing ventricu-
lar arrhythmias, particularly Torsades de Pointes (TdP). While 
this is a rare event, if it occurs, TdP can be life-threatening. 
However, not all drugs that prolong the QT increase this 
risk – some drugs that prolong the QT actually have anti- 
arrhythmic effects. Whether a drug increases the risk of TdP or 
not is believed to be determined by the mechanism of inhibition 
of ventricular repolarisation, and the duration of prolongation 
of the QT interval. TdP is treated with removal of the stimulus, 
intravenous magnesium, correction of electrolyte abnormalities, 
and DC cardioversion or overdrive pacing.
The mechanism of QT interval prolongation varies with dif-
ferent drugs and can be due to modulation of single or multiple 
currents involved in cardiac depolarisation32,33. Data suggest that 
modulation of a single current may be more likely to result in 
arrhythmias than QT prolongation due to modulation of mul-
tiple currents/channels34. The mechanism of QT prolonga-
tion with Tamoxifen in humans is unknown. In animals there is 
evidence that the block is multi-channel, due to both inhibition of 
the IKR and ICa channels, and may be therefore less likely to cause 
arrhythmia35–37. Supportive of a multichannel block mechanism 
for Tamoxifen is the fact that there are no case reports of TdP 
with Tamoxifen use, despite its extensive prescription.
Fluconazole can also result in QT prolongation. This is 
believed to be mediated through modulation of the IKR cur-
rent of the cardiac depolarisation cycle, but data are lacking 
concerning whether there are also effects on other currents38. 
TdP has been reported in patients receiving fluconazole, although 
again, this is a rare event39,40.
The effect of combining drugs that prolong the QT may depend 
upon the total number of mechanisms through which the 
QT is prolonged, and combining such drugs will not necessar-
ily increase the risk of TdP41,42. In this study, to mitigate any 
risk of prolonged QT, all patients will have meticulous moni-
toring and correction of electrolyte disturbances including 
potassium, calcium and magnesium, and twice daily ECG 
monitoring. The QT interval will be manually determined by 
measuring the interval in 3 limb and 3 chest leads, and 
determining the median (machine derived estimates of the QT 
interval are unreliable)43. The use of manual estimate of the QT 
has been shown to have similar performance to high resolu-
tion holter ECG monitoring43. Management of QTc prolongation 
will be in line with the recommendations of the American Heart 
Association32. The QT interval will be corrected (QTc) for rate 
using the Framingham formula. Where the QTc is found to 
be >500ms, the status of the patients K, Ca and Mg levels 
will be reviewed, corrected if necessary, and the ECG repeated 
before the next dose of Tamoxifen is due. If the QTc remains 
>500ms, the next due dose of Tamoxifen will be omitted 
until it is less than 500ms. When the QTc is less than 
500ms, Tamoxifen will be restarted.
Other effects
An early trial of high dose Tamoxifen (equivalent to 
>450mg/day) in patients with epithelial tumours reported a 
sense of light-headedness and unsteady gait in a proportion of 
patients, which resolved within 2–5 days of stopping the drug26. 
Tamoxifen does not have any expected haematological or 
hepatic side effects.
Drug interactions
Tamoxifen enhances the effects of warfarin and similar medi-
cations, which should be avoided. It is metabolised via the 
cytochrome p450 pathway and may elevate the levels of drugs 
metabolized through this pathway, including fluconazole. Phar-
macokinetic sampling will define whether there is any meas-
urable effect of Tamoxifen on fluconazole levels in this study. 
For all patients the drug history will be ascertained at 
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admission through the medical clerking and through 
examination of any accompanying medication where the patient 
is unsure of the nature of previously prescribed treatment.
Study aims
Primary aim
To determine whether adding Tamoxifen to standard anti-
fungal therapy increases the rate of clearance of yeast from 
cerebrospinal fluid in patients with cryptococcal meningitis. 
The rate of clearance will be defined as the Early Fungicidal 
Activity (EFA), as previously described8,9.
Secondary aims
The secondary aims are to
-    demonstrate the proof of concept that Tamoxifen 
can be safely administered with amphotericin and 
fluconazole to generate preliminary data that will support 
a larger phase 3 trial of Tamoxifen in cryptococcal disease
-    determine the effects on survival and disability at 
10 weeks following study treatment initiation,
-    define the pharmacokinetics of amphotericin, fluconazole 
and Tamoxifen in blood and CSF
-    better understand the pathogenesis of cryptococcal 
meningitis through defining the species, subtype, drug 
susceptibility and in situ gene expression of the infecting 
Cryptococcus and host response
Endpoints
Primary endpoint
The primary outcome is Early Fungicidal Activity (EFA), 
i.e. the rate of clearance of yeast from cerebrospinal fluid, over 
the first 2 weeks following randomisation. Repeated lumbar 
punctures are part of routine care for cryptococcal meningi-
tis in order to identify and manage raised intracranial pressure 
and to determine the response to treatment. In this trial, lumbar 
punctures are scheduled on days 1, 3, 7, 14, and additionally as 
clinically indicated. Whenever a lumbar puncture is performed 
we will determine the amount of viable yeast in CSF through 
culture. Based on the patients’ longitudinal quantitative yeast 
count measurements, EFA will be determined as described in 
the statistics section. Higher EFAs have been associated with 
better outcomes (survival and disability) in Vietnamese patients 
with cryptococcal meningitis8,9.
Secondary endpoints
Survival until 10 weeks after randomization. International 
treatment guidelines recommend 10 weeks of high dose anti-
fungal therapy for cryptococcal meningitis – an initial phase of 
amphotericin based induction therapy for 2 weeks followed by 
8 weeks of moderate to high dose fluconazole. The rate of 
survival until this 10 week period of therapy is completed 
is a frequent endpoint in trials of treatment for cryptococcal 
meningitis8,9,44. Improvements in EFA over the first 2 weeks 
of treatment have been associated with improved survival at 
10 weeks. Therefore survival until 10 weeks after randomization 
will be a secondary endpoint in this study.
Disability at 10 weeks. Disability is an expected consequence 
of cryptococcal meningitis, including blindness, deafness 
and other focal neurological deficits. In addition to improving 
the sterilizing power of antifungal therapy, Tamoxifen may also 
reduce the rates of disability in survivors. Neurological disabil-
ity will be assessed using the modified Rankin score and the Two 
Simple Questions and classified as good, intermediate, severe 
disability, or death, as previously described45.
Adverse events. The proportion of patients with any 
grade 3 or 4 adverse event, serious adverse event, or unexpected 
serious adverse event will be compared between treatment groups.
Rate of IRIS until 10 weeks (in HIV infected patients only). 
We will model the rate of IRIS over time with a cause-specific 
hazards model taking into account the competing risk of 
prior death. CM-related IRIS will be defined as per the recent 
proposed definition46.
Rate of Cryptococcal meningitis relapse. A pragmatic 
definition of relapse will be used. This is defined as either 
intensification of antifungal therapy above that according to 
the study antifungal schedule, or readmission for treatment of 
cryptococcal disease.
QT prolongation. Prolongation of the QT interval is a poten-
tial side-effect of both Tamoxifen and fluconazole, although 
it is not clear that either drug increases the risk of Torsade de 
Pointes, a potentially life-threatening arrhythmia. The QT 
interval will be estimated manually from 3 chest and 3 limb leads 
from a high resolution (50mm/sec) 12-lead ECG. The median 
value will be determined and used to calculate the corrected 
QT interval (QTc) using Framinghams’ formula.
Visual deficit at 10 weeks. Visual deficit occurs in 
5–40% of patients with cryptococcal meningitis depending 
upon underlying immune status5,8. The pathogenesis is unclear. 
We will compare the incidence of blindness and other visual 
deficit between treatment groups. Visual deficit will be assessed 
using a simple 6 point scale, as used in previous studies (see 
Table 3).
Time to new neurological event or death until 10 weeks. 
A neurological event is defined as a fall in Glasgow coma score 
by ≥2 points for ≥2 days from the highest previously recorded 
Glasgow coma score (including baseline) or the occurrence 
of any of the following adverse events: cerebellar symptoms, 
coma, hemiplegia, paraplegia, seizures, cerebral herniation, new 
onset blindness or deafness, or cranial nerve palsy.
Longitudinal measurements of intracranial pressure during 
the first 2 weeks. Intracranial pressure (ICP) will be measured 
at study entry, day 3, 7, and 14, and if clinically indicated 
(depending on local practice). The main outcomes are 
longitudinal ICP-measurements until day 14.
Clinical need and local practice will determine the frequency 
of lumbar punctures post day 14 and clinician’s diagnoses 
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of raised ICP based upon the presence of headache, nausea, 
diurnal and postural variation, relief with lumbar puncture 
and presence of papilloedema. Thus, these measures will 
only be descriptively analyzed.
CD4 count at 10 weeks. CD4 count measurement is 
indicated in HIV infected patients, and CD4 lymphopenia has 
been described in HIV uninfected patients with cryptococcal 
meningitis. Moreover, Tamoxifen may reduce CD4 cell 
apoptosis which may be beneficial47.
Blood and CSF concentrations of amphotericin, Tamoxifen 
and fluconazole. Pharmacological data on antifungal drugs 
are lacking. Dosing has been inferred from studies in 
healthy volunteers, or patients with other diseases. There 
are no studies of combination therapy at the doses currently 
recommended48–50, and no data on the effect of Tamoxifen on 
fluconazole concentrations. This study is an opportunity to 
improve our understanding of the pharmacokinetics and phar-
macodynamics of the currently recommended treatment combi-
nation in patients in a real world setting. It offers the chance to 
better understand how plasma concentrations of the drugs relate 
to clinical and microbiological outcomes, and therefore how 
treatment regimens might be improved. All patients will undergo 
pharmacokinetic sampling to enable the description of the 
concentrations of Tamoxifen and fluconazole in plasma and 
CSF, and of amphotericin in blood, and relate these to the 
rate of clearance of yeast from CSF. The yeast burden at each 
lumbar puncture will be determined using standard methods 
as in previous OUCRU studies9. PK and PD data will eventu-
ally be considered alongside data from the previously published 
CryptoDex trial9.
Pathogen and host gene expression. The second aim of the 
study is to improve understanding of the pathogenesis of CM 
by analyzing gene expression of both the pathogen and host. 
Fungi require a minimum set of interacting properties for patho-
genicity51–53. For Cryptococcus, it is clear that pathogenic-
ity factors identified to date represent only a fraction of the 
genes vital to cause disease52. Data suggest that variation in 
gene expression may be a major virulence determinant52–55. In 
Vietnam where we have identified 14 circulating lineages of 
C. neoformans, and found that lineage is associated with dis-
ease phenotype56. In particular, we have identified a clade 
(VNIγ) responsible for almost all (>92%) of cases in appar-
ently immunocompetent patients. We hypothesize that this strain 
has increased pathogenicity. These VNIγ strains also account 
for 35% of disease in HIV-infected patients. Whole genome 
sequencing of Vietnamese isolates has demonstrated substan-
tial differences between VNIγ and the most closely related clade, 
including over 100 gene insertions and deletions, and multi-
ple single nucleotide polymorphisms (≈40k)57. To better under-
stand exactly which genes define disease in HIV infected and 
uninfected patients, we will compare their relative expression 
according to infecting sequence type and host immune phenotype. 
Drainage of CSF to manage raised CSF pressure (see extended 
data appendix 158) is a key part of the usual management of 
cryptococcal meningitis, and together with the high burden 
of yeasts in CSF in cryptococcal disease, makes the measure-
ment of gene expression during disease using RNAseq feasible. 
Whenever a patient undergoes lumbar puncture, the CSF 
opening pressure will be measured and if elevated CSF will 
be drained according to international guidelines6. These 
state that the volume of CSF drained should be sufficient to 
reduce the pressure to half the opening pressure or to within the 
normal range (<18cm CSF) - whichever comes sooner. Typical 
volumes of CSF drained are 10–40ml. Following removal, 
CSF will be aliquoted for any indicated standard analyses (eg 
glucose, quantitative count, PK studies), and the remainder 
will undergo immediate processing for RNA extraction.
RNAseq is not organism specific and will not distinguish 
between pathogen and host (human) gene expression – all 
genes will be captured. However, yeast cells will be dominant 
in CSF and the majority of genes measured will be from Cryp-
tococcus. For patients who do not consent to having their 
own gene expression measured, only yeast gene expression will 
be analysed - the human signal will be subtracted. However, 
our past experience suggests that almost all patients are com-
fortable to take part in human genetic studies following 
explanation of the purpose of the study.
Design
Study design
A randomized, open-label trial with 2 parallel arms of stand-
ard antifungal therapy versus Tamoxifen augmented antifungal 
therapy during the first 2 weeks (induction phase) of treatment 
(see Figure 1). The study will recruit patients in two sites in 
Ho Chi Minh City, Viet Nam: the Hospital for Tropical Diseases 
(HTD), and the Department of Tropical Medicine, Cho Ray 
Hospital (CRH). The study is pragmatic, designed to maintain 
relevance through trialing Tamoxifen in the context of the best 
standard of locally available care. 25 patients will be enrolled 
into the two study arms (intervention versus control). All anti- 
fungal administration will be directly observed by ward staff.
Intervention arm: Induction phase treatment (days 1–14)
Tamoxifen will be given orally in a dose of 300mg/day for 
the first 14 days following randomization. It will be adminis-
tered by nasogastric tube where patients are unconscious. In 
addition patients will receive amphotericin 1mg/kg once 
daily i.v. and fluconazole 800mg once daily orally. The Tamoxifen 
will be administered in the morning combined with amphotericin 
and fluconazole dose.
Control arm: Induction phase treatment (days 1–14)
Patients will receive amphotericin 1mg/kg/day i.v. combined 
with fluconazole 800mg once daily orally for the first 
2 weeks. Amphotericin and fluconazole will be administered 
simultaneously.
Continuation phase of treatment (days 15–70)
After the first 2 weeks of study treatment, all patients will receive 
fluconazole 800mg/day for 8 further weeks, until the study 
end. At this point, HIV infected patients will be switched to 
long term secondary prophylaxis with fluconazole 200mg/day as 
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per standard practice. For HIV uninfected patients, the decision 
to continue antifungal treatment, and at which dose, will be 
made on a case by case basis by the attending physician in 
consultation with the patient.
Study Population
All HIV infected and uninfected adult patients with a diagno-
sis of cryptococcal meningitis presenting to the study centres 
will be eligible to enter the study, subject to meeting the inclusion/
exclusion criteria.
Trial Location
The study will recruit patients at sites on Ward E, Ward C 
and the Viet-Anh Ward, at HTD and in the Department of 
Tropical Medicine at CRH.
Inclusion criteria
•   Age ≥ 18 years
•    Cryptococcal meningitis defined as a syndrome consistent 
with CM and one or more of:
○    positive CSF India ink (budding encapsulated 
yeasts),
○   C. neoformans cultured from CSF or blood,
○    positive cryptococcal antigen Lateral Flow Antigen 
Test (LFA) in CSF
•    Informed consent to participate given by patient or 
acceptable representative
•    Known HIV infection status, or patient agrees to HIV 
testing on this admission
Exclusion criteria
•   Pregnancy or breast-feeding
•    History of thromboembolic disease such as pulmonary 
embolism or deep venous thrombosis
•   On anti-coagulant medication
•   On medication known to prolong the QT interval other than 
fluconazole, such as fluoroquinolones or antidepressants.
•   Known cardiac conduction defect including long QT 
syndromes
•   QTc at baseline > 500ms
•   Currently receiving treatment for cryptococcal meningitis 
and having received ≥4 days of anti-cryptococcal meningitis 
therapy
•   Known allergy to Tamoxifen
•    Currently or history of receiving treatment with Tamoxifen 
for breast cancer or other indication
•    Current or history of uterine cancer including endometrial 
cancer and uterine sarcoma
•    Renal failure (defined as creatinine>3*ULN, despite 
adequate hydration)
•    Failure to consent – the patient, or if they are incapacitated, 
their responsible relative, declines to enter the study
•   Allergy to amphotericin B or fluconazole
Study procedures
Recruitment
The target population for study screening is any patient 
known or suspected to have cryptococcal meningitis. To enter 
the study patients must be confirmed to have cryptococcal 
meningitis according to the definition in the inclusion criteria. 
According to the clinical care of the treating hospital, patients 
suspected of having cryptococcal meningitis will undergo:
a) an IMMY lateral flow cryptococcal antigen test (LFA) on serum, 
whole blood, plasma, or urine
AND/OR
b) blood culture for Cryptococcus 
AND/OR
c) a lumbar puncture with an lateral flow cryptococcal antigen 
test (Ref CR2003, IMMY, OK, USA), and/or microscopic 
examination of CSF, and/or culture of CSF. 
When the results of the IMMY lateral flow test (plasma, serum, 
urine or CSF), or CSF microscopy, or blood or CSF culture 
are available study staff may approach the patient regarding 
the study. Only patients 18 years or older who are not known 
to be pregnant and who have evidence of cryptococcal disease 
from one of the specified tests will be approached. 
A study staff member will invite the patient to discuss the 
details of the study. If the patient is judged by the staff to 
be unfit or unable to give informed consent, an accept-
able representative will act on their behalf for the following 
procedures. The study staff will give the patient/representa-
tive a copy of the informed consent form and explain the details 
of the study including the study procedures, risks and benefits, 
financial and confidentiality considerations, treatment alterna-
tives and how to obtain more information. The study staff will 
invite the patient/representative to ask questions and will 
endeavour to ensure that s/he understands the information 
given. The study staff will then ask the patient/representative to 
consider study participation. Those who refuse consent will 
be treated as per the best available standard care and will not 
have any study related procedures performed. 
Those who consent to the study will sign and date two copies 
of the informed consent form. The study staff will also sign and 
date the two copies. 
If the patient/representative is illiterate, a witness who is not 
a member of the study staff will be present during the informed 
consent discussion. The informed consent form will be read 
to the patient/representative in the presence of the witness. If 
the patient/representative agrees to participate, the form will be 
signed and dated by the witness. Consented patients will be 
screened for eligibility.
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Screening
Only patients who are 18 years or older, who are not 
known to be pregnant, and who have at least one of positive 
CSF or blood/serum/plasma/urine LFA test, positive blood or 
CSF culture, or positive CSF microscopy will be consented. 
Consented patients will undergo the following screening 
procedures/tests. In the case of an unconscious patient, 
information will be obtained from a knowledgeable relative or 
caregiver.
-    Medical history will be taken including: 1) signs and 
symptoms consistent with cryptococcal meningitis, 
2) allergy to Tamoxifen, 3) history of breast or uterine 
cancer, venous thromboembolic events and > 4 days 
anti-fungal therapy.
-    All females of child bearing age will have a urine or 
blood pregnancy test.
-   12 lead ECG to exclude cardiac conduction defects
-   Creatinine level.
-    HIV status will be confirmed from clinical history or 
testing as per standard of care. HIV testing is indicated 
and part of routine care for all patients with cryptococcal 
meningitis, since it defines the need for antiretroviral 
therapy and prophylaxis against other opportunistic 
infections.
-    A lumbar puncture will be performed on all patients to 
obtain CSF. The opening CSF pressure will be determined 
using a spinal manometer. CSF will be tested by: 1) India 
ink stain or equivalent, 2) quantitative culture, 3) lateral 
flow cryptococcal antigen test. Cultured isolates will be 
stored for subsequent studies. Residual CSF will be stored 
for cryptococcal gene expression studies which will be 
done in patients who pass screening and enter the full 
study.
-  If a lumbar puncture was done recently (within 
48 hours) for clinical care and volume of fresh 
CSF remains available for these tests (stored 
according to established SOPs), the lumbar puncture 
need not be repeated. 
-  If the patient underwent a recent lumbar puncture, 
an additional puncture will be performed (provided 
there are no contra-indications) if any of the 
following are true: 1) there is uncertainty regarding 
the microbiological diagnosis, 2) raised intracranial 
pressure is suspected, 3) the previous puncture 
was >2 days prior and no effective treatment has 
been given, 4) it is required for standard care. If 
none of the above are true or if the patient refuses 
further lumbar puncture, they may be randomized 
without additional lumbar puncture provided 
they are eligible for the study.
-  If the lumbar puncture was not recent, it will be 
repeated (provided there are no contraindications) 
in order to confirm the diagnosis, and to determine 
CSF pressure and fungal burden.
All lumbar punctures require verbal or written consent 
according to local standard clinical practice. Failure to consent 
is a contraindication to the procedure.
When all inclusion and exclusion criteria are verified, eligible 
patients will be randomized to treatment.
Patients who are determined to be ineligible will be withdrawn 
from the study and the reason recorded. Patients withdrawn 
from the study will be treated according to the best available 
standard care. Screening flow is illustrated in Figure 2.
The number of patients who do meet inclusion/exclusion 
criteria, but are not enrolled to the study will be recorded.
Randomization
Randomization will be 1:1 to either Tamoxifen augmented 
or standard antifungal therapy. Block randomization with 
stratification by hospital of enrolment and by HIV infection 
status, and variable block sizes of 4 and 6, respectively, will 
be used to assign subjects to treatment. The randomization list 
will be generated according to OUCRU standard operating 
procedures. In brief, the Research Biostatistician will set up 
statistical code to generate the randomization list and transfer 
it to the central Study Pharmacist. The Study Pharmacist will 
change the random seed, i.e. the initialization of the random 
numbers generator, in the statistical code in order to blind the 
Research Biostatistician and then run the code to prepare the 
final randomization list for treatment preparation. The rand-
omization list will be password protected and stored on a secure 
server to which only the Study Pharmacist has access.
Based on the randomization list, the central Study Pharmacist will 
generate identical sealed treatment packs for each study ID and 
distribute them to the sites in batches as required. All 
treatment packs will be identical in appearance and will contain 
either Tamoxifen and fluconazole or fluconazole alone. Each 
pack will contain sufficient fluconazole for the first 2 weeks of 
treatment. Enrolment logs specific to each ward will be used to 
assign patients to the next available sequential number and 
corresponding sealed treatment pack.
Patient management
Initial evaluation
On admission all patients will have a full clinical assessment 
and examination.
Study entry laboratory tests will be performed as per the 
study schedule in Table 2.
A baseline chest radiograph will be performed. A CT or 
MRI brain scan will be performed if there is evidence of raised 
intracranial pressure or focal neurological abnormalities 
according to local practice and resources.
Page 9 of 28
Wellcome Open Research 2019, 4:8 Last updated: 11 MAR 2019
Table 2. Trial Assessment and Investigation Schedule*.
Action
Day 
1(study 
Entry)
Day 3 Day 5 Day 7 Day 9 Day 11 Day 14 Day 21 Day28 Day 42 Day 70
Take informed consent X
Clinical Assessment ** X X X X X X X X X
Full blood count X X X
Sodium, Urea, Creatinine, 
Glucose X X X X X X X X X
Magnesium and Calcium X X X X X X X X
ALT and AST X X X
Potassium Daily for first 14 days X X
CD4 count In first week X
HIV test X
Blood cultures X
Cerebrospinal fluid (CSF) 
opening pressure X X X X if clinically indicated
Cryptococcal Lateral flow 
antigen test (CSF) X
CSF Gram’s stain, India ink X X X X
CSF cell count, protein, 
glucose X X X X
CSF TB smear/geneXpert During first week
CSF Yeast quantitative 
culture X X X X
Store C. neoformans 
isolate X X X X
CSF for Pharmacokinetics X X X
Plasma for 
pharmacokinetics X X
Sputum TB smear*** X
Electrocardiogram Twice daily for first 14 days
Chest X-ray X
Approximate total blood 
volume mL 21.5
Approximate total CSF 
volume mL
up to  
25
up to 
25
up to 
25
up to 
25
up to 
25
up to 
25
up to 
25
up to 
25
* Study drug is given daily from day 1 – day 14** GCS Assessment is daily while an in-patient. When outpatient, assessment can take place at the scheduled 
time + up to 5 days (e.g. 4 week assessment on day 28-33). ***at doctor’s discretion **** volume determined by CSF pressure N.B.: Blood volumes are 
estimates
Table 3. simple visual assessment.
Record the best performance of each eye
Function Score
Normal 1
Blurred 2
Finger counting 3
Movement perception 4
Light perception 5
No light perception 6
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Figure 1. Trial design and flow diagram.
Hospital admission
Intravenous amphotericin B is administered for 14 days 
necessitating hospital admission during this period. Study treat-
ment and antifungals will be directly administered during this 
time period.
Clinical monitoring
Patients will have daily Glasgow Coma Score and review as 
per standard care until discharge from hospital. The decision 
to discharge patients from the hospital is at the attending phy-
sician’s discretion and is based upon the clinical status of the 
patient. Following discharge patients will be seen weekly 
until 4 weeks, at 6 weeks and at 10 weeks. If the exact visit 
day is not feasible, scheduled visits can occur at up to 5 days 
following the stipulated time to account for weekends and 
holidays (for example, the 4 week review should occur at on 
day 28–33 following randomisation, week 10 visit on day 70–75). 
Patients will be monitored closely for
•   Death - the date of death and cause will be recorded
•    New neurological events (onset of new focal neurologi-
cal signs or fall in Glasgow coma score of ≥ 2 points for 
≥ 2 days, following > 7 days clinical stability or 
improvement after randomization)
•   Drug-related adverse events
•   New or recurrent AIDS defining illnesses
•   Visual deficit (at week 10)
•   IRIS
•   Raised intracranial pressure (clinical or measured)
Uniform management of patients and recording of data 
will be ensured by the local study staff who will do clinical 
assessments daily while admitted and at follow-up visits. 
Uniform management and data recording will be ensured through 
training of study staff, standard operating procedures for the 
administration of drugs and identification and management of 
specific complications, and the use of a clinical reporting form 
that has been developed in previous OUCRU studies. The 
study has a follow-up period of 10 weeks post-randomisation, 
and the full study analysis will be performed and the data sub-
mitted for publication when the last patient under follow-up has 
reached this timepoint.
Adherence monitoring
All administration of study and antifungal drugs will 
be directly observed and recorded in the treatment medication 
sheet of the CRF during the in-patient stay. On discharge, sufficient 
fluconazole will be dispensed to meet the patient’s needs until 
10 weeks following randomization, plus 3 extra days. At each 
study visit a pill count will be performed to monitor adherence 
to antifungal therapy.
Cardiac monitoring
ECGs (50mm/sec) will be performed twice daily immedi-
ately before and 2 hours after administration of Tamoxifen 
during the first 14 days, and on days 21 and 28. ECGs can 
be repeated more frequently according to the patient’s needs. 
The QTc will be calculated as described in section ’Prolongation 
of the QT Interval’.
Laboratory monitoring 
Blood
Inpatient laboratory monitoring will be as shown in the 
study schedule (Table 2). Patients will have daily monitoring 
of potassium and alternate day monitoring of creatinine, cal-
cium and magnesium levels for the first 2 weeks of the study(i.e. 
days 1, 3, 5, 7, 9, 11, and 14. Following this point levels will be 
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???????????????????????
?????????????????????
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Figure 2. Estimated power based on the two simulation studies.
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monitored as clinically indicated. Full blood count will be 
measured at study entry, and at days 7 and 14, and thereafter 
as clinically indicated. CD4 count will be measured in all 
patients during week 1 and at day 70.
Cerebrospinal fluid
Lumbar puncture will be performed on days 1, 3, 7 and 
14 following randomization. CSF opening and closing pres-
sure will be measured on each sampling. Following the initial 
diagnostic lumbar puncture, routine diagnostic investigations 
will be performed according to clinical need. Whenever CSF 
is sampled, the fungal burden will be determined by culture 
(0.5mL), an aliquot immediately processed and frozen to -80°C 
for subsequent drug level measurement (1-1.5mL), and the 
remainder of any CSF (ie above that needed for clinical care 
and the PK measurements, and between 1-40mls, depending 
upon the amount needed to be removed to manage the CSF 
pressure) immediately processed for RNA extraction for gene 
expression studies. Rarely (approximately 0.5%) TB menin-
gitis can occur at the same time as cryptococcal meningitis. 
Patients should have CSF tested by GeneXpert or smear or other 
nucleic acid amplification test during the first week of study 
treatment.
PK sampling
Plasma sampling for PK
Participation in the plasma PK study will require additional 
consent from the patient. Patients who agree to participate 
will have baseline bloods taken prior to medication being given, 
but amphotericin will be prepared, ready for administration, 
so that the infusion can commence without delay follow-
ing venesection. 1.5ml of blood will be taken in a plain tube 
and transported in iced water to the laboratory where it will be 
immediately centrifuged and the plasma frozen to -80°C for 
storage. This will be the 0hr sample. The standard 4 hour 
amphotericin infusion will then commence, and oral fluco-
nazole and Tamoxifen will be administered. Patients will be 
sampled for PK a total of 5 times each on day 1 and day 7. 
The total volume of blood drawn will be 7.5mL on each day. 
The exact timing of blood draws is currently being modelled 
based on previous Vietnamese data by Prof Hope in Liverpool, 
such that the most efficient sampling schedule is used. 
The timing of administration of all antifungal drugs will be 
meticulously recorded. In addition, every time a lumbar puncture 
is performed, a paired plasma sample will be taken (1.5mL).
CSF sampling for PK
PK CSF sampling will not require additional lumbar punctures 
(see section ’Clinical Monitoring’, subsection ‘Cerebrospinal 
fluid’). Rather, the timing of all lumbar punctures will be metic-
ulously recorded along with the timing of antifungal drug 
administration. 1-1.5ml of CSF will be required for PK studies. 
PK studies will only be done if there is sufficient sample available 
after routine clinically indicated investigations have been 
performed. Every time a lumbar puncture is performed, a paired 
plasma sample (1.5mL) will be taken for drug concentration 
determination (see section ‘Laboratory Monitoring’, subsection 
‘PK Sampling’).
Other investigations
Other investigations may be performed as clinically indicated. 
Data for the following will be recorded when performed for 
routine clinical care:
•    CSF, if neurological deterioration (Gram stain and routine 
culture, ZN stain and mycobacterial culture, India ink stain 
and fungal quantitative culture)
•   Sputum, if symptomatic (routine culture, ZN stain)
•   Urine culture, if urinary symptoms (urine culture)
•    Stool culture, if prolonged diarrhoea (microscopy, culture 
and parasites)
•   Blood cultures, if persistent fever
•    Lymph node aspiration (routine and mycobacterial 
cultures)
•    Blood glucose will be measured when CSF is examined or 
if hyper or hypoglycaemia is suspected
•    Liver function tests
A window period of +/- 2 days outside of the scheduled 
laboratory tests will apply to all tests except for electrolytes 
including potassium, magnesium and calcium, and those needed 
at baseline for inclusion/exclusion criteria.
Evaluation of Cryptococcus isolates
All Cryptococcus isolates will be speciated using classical 
mycological and molecular methods, and typed through genome 
sequencing and phenotypic testing. All isolates will undergo 
susceptibility testing for antifungal drugs and Tamoxifen. Isolates 
will be securely stored in OUCRU, HTD.
Imaging
A chest X-ray will be performed on study entry if it has 
not been done at the time of diagnosis. The result will be 
recorded in the CRF. Brain imaging is not mandated by the 
study. The decision to perform brain imaging will be accord-
ing to local practice. Results of brain imaging when available 
will be recorded. The brain imaging modality of choice will be 
MRI.
Other treatment 
Antifungal treatment
All patients – control and intervention arm - will receive anti-
fungal treatment consisting of 2 weeks of intravenous ampho-
tericin B 1mg/kg/day combined with high dose fluconazole 
(800mg once daily), followed by fluconazole 800mg once 
daily for 8 weeks (10 weeks in total). This is locally feasible 
and consistent with recent guidelines6,7. Amphotericin will be 
administered according to recommended guidelines (see 
extended data, appendix 258). Following the 10 week period of 
therapy, HIV infected patients, provided they have responded 
to treatment, will receive long term secondary prophylaxis 
with fluconazole 200mg/day as per standard of care7. For 
HIV uninfected patients, the dose of antifungal therapy after 
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10 weeks will be determined on a case by case basis depend-
ing on response to treatment and the attending physician’s 
judgement regarding the likelihood of there being some other 
chronic immunosuppressive condition. After the initial 2 weeks 
of the study, modification of antifungal therapy for any patient 
can be made according to the patient’s needs and the judgment 
of the attending physician. Any changes to antifungal therapy 
will be recorded in the case record form. The cost of antifungal 
treatment until 10 weeks following randomization will be 
covered by existing local financial support or trial finances. 
Following the final follow-up visit patients will continue in care 
under the existing local services.
Antiretroviral therapy
All HIV infected patients will be referred to local HIV 
services as soon as practicable, preferably while still admitted 
to hospital, to ensure that they have access to locally available 
HIV services including counseling and ARVs.
The recent COAT trial suggests that early (within 5 weeks 
of diagnosis and institution of effective antifungal therapy) intro-
duction of ARVs is associated with worse outcomes. Therefore 
the study protocol recommends that ARVs are begun at least 
5 weeks after institution of antifungal treatment, provided 
the patient has made a good response. The date that ARVs 
are started (or stopped) in patients in the study will be recorded. 
Where a patient is already receiving ARVs at the time of 
diagnosis, the decision to continue them will depend upon 
the decision of the local attending physician who will make 
a judgement regarding whether the cryptococcal meningitis 
represents antiretroviral failure or not.
Opportunistic infection (OI) prophylaxis for 
immunosuppressed patients
HIV infected patients will be profoundly immunosuppressed 
and will receive prophylactic therapy against pneumocystis 
pneumonia with daily trimethoprim-sulfamethoxazole, in accord-
ance with local guidelines and practices. If other patients with 
non-HIV related immunosuppression are identified, then they 
will receive OI prophylaxis according to the local physicians’ 
judgement.
Data on concomitant medications
At each visit, information on other medications, including 
start dates and reason for taking them, will be documented in the 
case record forms. 
Management and prevention of potential cardiac 
adverse events
Possible side effects of Tamoxifen are described earlier.
Electrolyte disturbances and raised creatinine
Electrolyte disturbances are common in cryptococcal disease, 
usually precipitated by amphotericin treatment. The likelihood 
of such disturbances are mitigated by pre-emptive electrolyte 
replacement, sodium loading, and ensuring adequate hydration. 
It is routine practice to administer 2 litres of normal saline and 
80mmol/L of potassium chloride daily to patients receiving 
amphotericin treatment. All patients in the study will receive 
such pre-emptive fluid and electrolyte replacement unless they 
are fluid overloaded or have elevated serum potassium concen-
trations. In the event of the serum creatinine being greater than 
300umol/L, the next amphotericin dose will be missed, and 
the hydration status of the patient re-assessed and corrected. 
Amphotericin will be restarted when the serum creatinine is 
<200umol/L.
Prolonged QTc
Prolongation of the QT interval will be actively monitored 
with daily pre and 2 hour post Tamoxifen dose 12 lead ECGs at 
50mm/s for the first 2 weeks of treatment, and weekly after 
that, unless they are indicated more frequently. Trained study 
staff will measure and calculate the corrected QT interval. 
It is expected that around 10–50% of patients will develop 
prolonged QTc intervals while on treatment13,16. With some 
drugs, a prolonged QTc can lead to a polymorphic ventricu-
lar tachyarrhythmia (Torsades de Pointes, TdP) which can be 
life threatening. However, this has not been described in patients 
receiving Tamoxifen, including in those receiving higher 
doses as will be used in this study12,13,16,26. Prolongation of the QT 
interval has also been reported in patients receiving fluconazole, 
but TdP has only rarely been described with less than 10 reports 
published at the time of writing, despite its extensive use38,40. 
Moreover, in a case series of cancer patients receiving fluoro-
quinolones (which also prolong the QT interval) combined with 
fluconazole, despite QT prolongation there were no episodes of 
arrhythmias42. In this study QT prolongation will be managed in 
line with American Heart Association guidelines as described 
below32. Any risk of TdP will be mitigated by close monitoring 
and management of electrolytes, particularly potassium, cal-
cium and magnesium. The use of other drugs which can prolong 
the QTc and have been associated with TdP, other than fluco-
nazole, will be prohibited during the first 14 days following 
randomization. Appendix 4 of Extended data58 lists such drugs.
If the QTc is >500ms,
1.    Do not administer further tamoxifen until the QTc is 
≤ 500ms.
2.    Immediately recheck blood potassium, calcium and 
magnesium levels.
3.   Complete a Cardiac Adverse Event form from the CRF
4.    Correct abnormal electrolytes into the mid normal range 
with intravenous supplementation (potassium chloride, 
calcium gluconate or chloride, and magnesium sulfate). 
Use intravenous access separate to the amphotericin 
infusion when administering electrolytes.
5.    Repeat the ECG, a 30 second rhythm strip, and serum 
electrolytes 2 hours prior to the next due dose of 
Tamoxifen.
a)    If the QTc is >500ms, the due dose of tamoxifen 
should be omitted.
b)    If the QTc is ≤500ms but there are extra-systoles, the next 
dose of tamoxifen should be omitted
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c)    If the QTc is ≤500ms and there are grade 2 or greater 
abnormalities in serum potassium, magnesium or 
calcium levels, the next dose of tamoxifen should be 
omitted.
d)    If the QTc is ≤500ms, and there are no extra-sytoles, 
and the calcium, potassium and magnesium levels are 
normal or no more than grade 1 abnormal, the next 
due dose of tamoxifen can be given.
6.    Where the QTC is >500msec, the administration of 
tamoxifen is suspended and the patient must
a)    have daily ECGs and monitoring and correction of 
electrolytes until the QTc is less than 500ms.
b)    When the QTc is <500ms, Tamoxifen can be restarted 
according to the guidance in 5 a-d above.
7.    Tamoxifen is administered until day 15 after 
randomization. All due, received and missed drug 
doses must be recorded in the study case record form 
(CRF).
8.    Any patient where the QTc is greater than 500ms 
AND is accompanied by syncope OR arrhythmia 
should have review by a cardiologist.
Ventricular tachyarrhythmia
In the event of TdP or any other ventricular tachyarrhythmia, 
patients will receive oxygen and be transferred to a high care 
environment for continuous cardiac monitoring. If there is car-
diovascular compromise, resuscitation will follow normal 
practice. Electrolytes will be rechecked, corrected if needed, 
and administration of Tamoxifen and fluconazole suspended.
TdP usually occurs in unsustained bursts that spontane-
ously terminate. However, the specific treatment of TdP is 
intravenous magnesium, given as Magnesium sulfate in a 
dose of 1–2 g intravenously over 5 to 10 minutes diluted in 
50–100mls of 5% dextrose. This can be repeated in 
5–15 minutes. Alternatively, a continuous infusion can be 
started at a rate of 3–10 mg/min. Note: Magnesium is effective 
even in patients with normal magnesium levels.
Temporary transvenous pacing can be used to treat refrac-
tory TdP. Temporary pacing is used based on the fact that 
the QT interval shortens with a faster heart rate. Therefore, pac-
ing can be effective in terminating torsade. Atrial pacing is the 
preferred mode because it preserves the atrial contribution to 
ventricular filling and also results in a narrower QRS complex 
and hence a shorter QT. Pacing should be instituted at a rate of 
90–110 bpm until the QT interval is normalized. Overdrive 
pacing may be necessary at a rate of up to 140 bpm to control 
the rhythm.
Patients who are in extremis with TdP, or who develop ventricu-
lar fibrillation, should be treated with electrical cardioversion or 
defibrillation. 
All arrhythmias are adverse events and must be recorded on 
the appropriate form in the CRF.
Patients who have arrhythmias should be reviewed by a 
cardiologist.
Fluconazole should be restarted when the arrhythmia is 
resolved for 24 hours. Tamoxifen will not be restarted for any 
patient who has a ventricular tachyarrhythmia.
Syncope
Any patient who has sudden onset of loss of consciousness 
will be assessed by a clinician according to normal practice. 
ECG and electrolytes will be checked and corrected. The 
patient will be monitored in a high care environment. Tamoxifen 
administration will be stopped and not restarted. Patients who 
have syncope due to suspected arrhythmia should be reviewed by 
a cardiologist.
Stopping study drug
Occasionally it can be necessary to stop the study intervention 
(Tamoxifen). Stopping a patient’s treatment does not mean that 
they have withdrawn from the study. Patients continue in the study 
and follow the protocol schedule for visits and investigations 
until its conclusion.
Indications for stopping Tamoxifen
Tamoxifen is generally a well tolerated drug. Studies from 
breast cancer suggest increased risks of pulmonary embolism, 
and uterine malignancies, but the absolute risks of these are 
very low and they are associated with prolonged use over many 
months rather than short course duration, as will be used in this 
study29. It is unlikely that the 2 weeks duration of treatment in 
this study will increase these risks. Prolongation of the QTc 
interval is to be expected in this study and does not necessarily 
indicate a risk of ventricular arrhythmia. The management of 
study drug in the face of prolonged QTc (>500ms) has been 
described in section ‘Management of Adverse Events’, subsec-
tion ‘Prolonged QTc’. However, Tamoxifen will be stopped 
and not restarted if any of the following events occur in a 
particular patient:
1.   deep venous thrombosis
2.   venous thromboembolism
3.   syncope
4.   ventricular tachyarrhythmia
Withdrawal from the trial
Patients may voluntarily withdraw from the trial for any rea-
son. If this occurs, the patient will be referred to standard 
clinical care facilities. The patient’s withdrawal from the trial 
will not affect their access to the best standard of care within the 
local health system. With the agreement of the patient, clinical 
and laboratory assessment should be performed and recorded at 
the time of withdrawal. Patients may also decide to stop study 
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treatment without withdrawing from the study, in which case 
Tamoxifen will be stopped and follow-up will continue as per 
the study schedule.
Adverse events
Definition of adverse events
An adverse event (AE) is any undesirable event that occurs 
to a study participant during the course of the study whether or 
not that event is considered related to the study drug. An AE can, 
therefore, be any unfavorable and unintended sign (including 
an abnormal laboratory finding, for example), symptom, or dis-
ease temporally associated with the study drug, whether or not 
considered related to the study drug.
Examples include:
•    An increase in severity (grade) or frequency of a pre-exist-
ing abnormality or disorder (events that are marked by a 
change from the participant’s baseline/entry status, includ-
ing changes in blood tests such as electrolytes)
•   All reactions from sensitivity or toxicity to study drug
•    Injuries or accidents (e.g., for a fall secondary to 
dizziness, “dizziness” is the event and the injury secondary 
to the fall is the “outcome”)
•    New clinically significant abnormalities in clinical 
laboratory values, physiological testing or physical 
examination.
Stable chronic conditions, such as arthritis, which are present 
prior to clinical trial entry and do not worsen are not 
considered AEs and will be documented in the subject’s clinical 
chart as medical history. 
Clinical or laboratory events are considered adverse events 
only if they occur after the first dose of study treatment and 
before the patient completes trial participation. (See below for 
reporting of adverse events.)
Definition of Serious Adverse Events
An AE is considered to be “serious” if it results in one of the 
following outcomes
•   Death,
•    Life-threatening event (the subject was at immediate 
risk of death at the time of the event; it does not refer 
to an event which hypothetically might have caused 
death if it were more severe),
•    Inpatient hospitalization or prolongation of existing 
hospitalization
•    Persistent or significant disability/incapacity (a substan-
tial disruption of a person's ability to conduct normal 
life functions),
•   Congenital anomaly/birth defect
•    Important medical event that may not be immediately 
life-threatening or result in death or hospitalization but 
may jeopardize the patient or may require intervention 
to prevent one of the other outcomes listed in the 
definition above.
Definition of Unexpected Serious Adverse Events
Unexpected Serious Adverse Events are untoward medical 
events which fit one or more of the criteria for SAEs above 
and which are not considered a part of normal clinical 
progression of disease or an expected drug reaction. Any event 
which becomes of concern to the investigators or study doctors 
during the course of the trial may be reported as a USAE.
Assessment of Adverse Events
Adverse events will be defined according to the Common 
Terminology Criteria for Adverse Events (CTCAE). New AIDS 
defining events will be defined according to the revised CDC 
criteria modified for this trial (see extended data, Appendix 358). 
In the event that an adverse event is not described within the 
CTCAE definitions, or is a new AIDS defining event, the 
following generic severity grading will be used: 
Grade 1 Mild; asymptomatic or mild symptoms; clinical or 
diagnostic observations only; intervention not indicated.
Grade 2 Moderate; minimal, local or noninvasive interven-
tion indicated; limiting age-appropriate instrumental Activities of 
Daily Living (ADL)*.
Grade 3 Severe or medically significant but not imme-
diately life-threatening; hospitalization or prolongation of 
hospitalization indicated; disabling; limiting self-care ADL**.
Grade 4 Life-threatening consequences; urgent intervention 
indicated.
*Instrumental ADL refer to preparing meals, shopping for 
groceries or clothes, using the telephone, managing money, etc.
**Self-care ADL refer to bathing, dressing and undressing, 
feeding self, using the toilet, taking medications, and not bedrid-
den.
[Note: “Life-threatening” as a severity grade is not necessar-
ily the same as “life-threatening” as a “serious” criterion used to 
define a serious adverse event. The former is a “potential” threat 
to life and the latter is an “immediate” threat to life.]
A laboratory abnormality only needs to be recorded as a 
clinical adverse event if it is associated with an intervention. 
Intervention includes, but is not limited to, discontinuation of a 
current treatment, dose reduction/delay of a current treatment, 
or initiation of a specific treatment. In addition, any medically 
important laboratory abnormality may be reported as an adverse 
event at the discretion of the investigator. This would include 
a laboratory result for which there is no intervention but 
the abnormal value suggests a disease or organ toxic-
ity. Laboratory events will be graded according to CTCAE 
definitions.
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If clinical sequelae are associated with a laboratory abnormal-
ity, the diagnosis or medical condition should be reported as the 
adverse event (e.g., renal failure, haematuria, cardiac 
arrhythmia) - not the laboratory abnormality (e.g., elevated 
creatinine, urine RBC increase).
Recording and reporting of Adverse Events and 
protocol violations
Adverse event recording
Grade 3 and 4 adverse events will be recorded in the case 
report form and entered to the study database. Grade 1 & 2 events 
will not be recorded since in a severe disease such as cryptococ-
cal meningitis the number of low grade adverse events is likely 
to be high representing a large reporting burden which may impact 
upon the quality of recording and reporting of more important 
grade 3 and 4 adverse events.
Adverse event reporting
Serious adverse events and serious unexpected adverse 
events will be reported to the Principal Investigator within 
3 days of occurrence, or sooner according to local 
requirements. The Principal Investigator will report all unex-
pected serious adverse events to the DSMB within 10 days of 
occurrence. Unexpected serious adverse events will be reported 
to the responsible ethical committees within 10 days of 
occurrence or as required by the committee. Serious adverse 
events will be reported to the local IRBs on a monthly basis.
Protocol violations
Protocol violations are events which contradict or omit proto-
col instructions. Violations which compromise patient safety 
or the integrity of trial data will be recorded and reported to the 
responsible Ethics Committees as required by the regulations 
of each Committee.
Statistics
Sample size and power considerations
Sample size considerations were based on simulation using 
data from two previously published trials in cryptococcal 
meningitis conducted in Vietnam8,9: 96 patients from the BK trial 
(all recruited at HTD) with at least one quantitative fungal count 
measurement randomized to amphotericin B plus fluconazole, 
and 97 randomized to amphotericin B plus flucytosine; 
plus 49 patients from the CryptoDex trial recruited at HTD or 
Cho Ray Hospital randomized to placebo (all of these received 
antifungal treatment with amphotericin B plus fluconazole).
The first set of simulations assumed that the Tamoxifen group 
was associated with a similar effect on Early Fungicidal Activity 
(EFA) as amphotericin B plus flucytosine. For sample sizes 
ranging from 15-30 patients per group, we repeatedly sampled 
patients from both included BK study arms of that size with 
replacement, analyzed them, i.e. compared EFA between the two 
groups, and then determined the proportion of significant results 
(i.e. the estimated power).
For the second set of simulations, the control group consisted 
of the combined 145 patients from the BK study and 04CN 
receiving amphotericin B plus fluconazole. For assumed EFA 
treatment effects ranging from -0.16 to -0.10 log10CFU/ml 
per day faster declines in the intervention group, we generated 
hypothetical intervention group data by simulating this treat-
ment effect on top of the observed fungal count measurements for 
patients receiving amphotericin B plus fluconazole. Power was 
then determined based on resampling-based simulation as for 
the first set of simulations.
Estimated power was based on 10 000 repetitions of each simu-
lation experiment. Estimating EFA based on a mixed model 
accounting for the detection limit of fungal count measurements 
was not feasible because this would require excessive computing 
time. Thus, we used a simple mixed model ignoring the detec-
tion limit for the simulations instead but removed values after 
the first undetectable (zero) fungal count measurements and 
kept the first fungal count of zero only if it lead to a steeper 
estimated least-squares decline for that patient compared to 
omitting the measurement.
Results for both sets of simulations are shown in Figure 3. 
Based on the first simulation study, n=25 subjects per group pro-
vide approximately 80% power to detect a difference in EFA 
of similar size as the difference between amphotericin B plus 
fluconazole and amphotericin B plus flucytosine observed in 
the BK study. Based on the second simulation study, n=25 
subjects per group provide 80% and 90% power to detect a dif-
ference in EFA of -0.11 or -0.13 log10CFU/ml/day, respectively. 
We consider that this size of effect is likely to deliver a clinical 
benefit. All simulations were performed using R software 
version 3.2.259.
Analysis
Analysis of the primary endpoint: early fungicidal 
activity (EFA)
All recorded longitudinal quantitative fungal count measure-
ments up to day 17 (allowing for some delays in the day 14 
measurements) will be included in the analysis. EFA will be 
modeled based on a linear mixed effects model with longtitudi-
nal log10-CSF quantitative culture fungal counts as the outcome, 
interaction terms between the treatment groups and the time since 
enrolment of the measurement as fixed covariates and random 
patient-specific intercepts and slopes. The lowest measurable 
quantitative count is 5 CFU/ml and values below the detection 
limit (which correspond to recorded values of 0) will be treated 
as <4.5 CFU/ml, i.e. non-detectable measurements will be 
treated as left-censored longitudinal observations in the analysis 
as we have done previously8.
Based on this model, EFA will be compared between the 
two treatment arms in all patients (intention to treat), in the 
per-protocol population, and subgroups defined by HIV sta-
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Figure 3. Screening study flow diagram.
tus (uninfected; infected) and baseline fungal burden (<5 log10 
CFU/ml; ≥5 log10 CFU/ml).
Analysis of secondary endpoints
Survival until 10 weeks after randomization
Overall survival will be visualized using Kaplan-Meier curves 
and modeled using the Cox proportional hazards regression 
model with stratification by HIV status. In addition, survival will 
be modeled with a multivariable Cox regression model includ-
ing the following covariates in addition to the treatment group: 
baseline log10-fungal load, Glasgow coma score less than 15 
(yes or no), HIV infection status, and ARV treatment status 
at study entry (naïve or experienced).
Disability at 10 weeks.
The disability score at week 10 follow-up is defined as the 
higher (worse) of “ the two simple questions” and the Rankin 
score assessed at that time point, and will be categorized as good 
outcome, intermediate disability, severe disability, or death (in 
case the patient died before 10 weeks) as previously described45. 
The ordinal 10-week score (“good”>”intermediate”>”severe”>
”death”) will be compared between the two arms with a propor-
tional odds logistic regression model depending on the treatment 
arm and HIV infection status. The result will be summarized as 
a cumulative odds ratio with corresponding 95% confidence 
interval and p-value. Patients lost to follow up will be analyzed 
according to their last recorded disability status. If the rate of 
patients lost to follow-up exceeds 10%, we will also perform an 
alternative analysis based on multiple imputation of missing 
values.
Adverse events.
The frequency of serious and grade 3 & 4 adverse reactions 
as well as the frequency of specific adverse events will be 
summarized (both in terms of the total number of events as 
well as the number of patients with at least one event). The 
proportion of patients with at least one such event (overall 
and for each specific event separately) will be summarized 
and (informally) compared between the two treatment groups 
based on Fisher’s exact test.
QT prolongation
The QTc will be classified as “normal” (<450ms for males, 
<460ms for females), mildly prolonged (≥450ms for males or 
≥460 for females but ≤500ms) and prolonged (>500ms). The 
frequency of patients with a maximum QTc in these categories 
will be summarized for the following time intervals: day 1 
(baseline), days 2-3, 4-7, 8-14, and after day 14. Comparisons 
will be with a proportional odds logistic regression model 
depending on the treatment arm and HIV infection status.
The maximum absolute change from baseline of the QTc 
during follow-up will also be summarized; the comparison 
between treatment groups will be based on a linear regression 
model with treatment as the main covariate and adjustment for 
HIV status and the baseline QTc interval.
Analysis of other secondary outcomes
The rate of IRIS and the rate of relapse (defined as antifungal 
treatment intensification or re-treatment) will be modeled with 
cause-specific proportional hazards models with treatment as the 
only covariate and stratification by HIV infection status.
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The visual acuity at 10 weeks is recorded on a 6 point scale and 
will be summarized by treatment arm for each eye separately, 
and overall where “overall” is defined as the worst recorded acu-
ity of either eye. The odds of having “normal acuity” (amongst 
all surviving patients with a visual assessment) will be infor-
mally compared between the treatment arms with a logistic 
regression model adjusted for HIV status.
The time to the first new neurological event or death until 
10 weeks will be analyzed in the same way as overall survival. 
Longitudinal measurements of intracranial pressure during the 
first 2 weeks will be modeled using a mixed effect model as 
described for the primary outcome. CD4 cell count at baseline 
and 10 weeks will be summarized and the change compared 
between the two groups based on a linear regression model with 
treatment as the main covariate and adjustment for HIV status 
and baseline CD4 cell count.
Analysis populations
The primary analysis population for all analysis is the full 
analysis population containing all randomized patients except 
for those mistakenly randomized without cryptococcal meningi-
tis. Patients will be analyzed according to their randomized arm 
(intention-to-treat). In addition the primary endpoint will 
be analyzed on the per-protocol population which will exclude 
the following patients: major protocol violations and those 
receiving less than 1 week of administration of the randomized 
study drug for reasons other than death.
Interim analysis and role of the Data and Safety 
Monitoring Board (DSMB)
An independent DSMB will oversee the trial. Cardiac and 
unexpected serious adverse events with treatment allocation 
blinded will be reported to the DSMB within 10 days of occur-
rence and followed-up until resolution. The DSMB will 
perform an unblinded safety analysis after the first 20 patients 
have completed the allocated 2-week induction treatment or died. 
Particular attention will be paid to cardiac adverse events. Stop-
ping for harm of Tamoxifen will be considered if a safety issue 
emerges which is sufficiently large, in the judgement of the DSMB, 
to suggest that continued exposure of patients to Tamoxifen 
is unethical. Early stopping for efficacy of Tamoxifen is not 
foreseen as this is a pilot study. The DSMB will be able to 
mandate additional safety analyses at any timepoint they deem fit.
At the interim analyses, the DSMB will receive a report 
including summaries of mortality, serious adverse events, 
grade 3 & 4 adverse events, and estimates of early fungicidal 
activity during the first 14 days by treatment arm. The report 
will be prepared by the DSMB statistician and distributed to all 
DSMB members for review. Based on these data, the committee 
will make recommendations on the continuation, cessation 
or amendment of the study. The study statistician will aid in 
setting-up the code for generating the interim analysis summa-
ries in a blinded fashion, i.e. without access to the randomization 
assignment. The randomization list will be sent to the DSMB 
statistician directly from the study central pharmacist.
As the dissemination of preliminary summary data could 
influence the further conduct of the trial and introduce bias, 
access to interim data and results will be confidential and 
strictly limited to the involved independent statistician and the 
monitoring board and results (except for the recommendation) 
will not be communicated to the outside and/or clinical 
investigators involved in the trial.
Further reviews will be at the discretion of the DSMB. All 
DSMB reports, replies or decisions will be sent to the responsible 
Research Ethical Committees.
Ethical considerations
Declaration of Helsinki and Good Clinical Practice
The Investigator will ensure that this study is conducted 
in compliance with the current revision of the Declaration of 
Helsinki (Seoul 2008) and the Medical Research Council 
Guidelines on Good Clinical Practice (1998).
Ethical Review
The study has been approved by the Oxford Tropical Research 
Ethics Committee (Reference 25-16), The ethics Committees of 
the Hospital for Tropical Diseases, Ho Chi Minh City (Reference 
CS/ND/17/07) and Cho Ray Hospital, Ho Chi Minh City 
(Reference 179 – CN-HDDD), and the Vietnam Ministry of 
Health (reference 3110/QD-BYT).
Informed consent
The study staff will discuss the study with all potential adult 
participants or, in the case of a participant who is unable to give 
informed consent independently, with a representative appro-
priate within local culture. Study staff will describe the pur-
pose of the study, the study procedures, possible risks/benefits, 
the rights and responsibilities of participants, and alternatives 
to enrolment. The participant or representative will be invited to 
ask questions which will be answered by study staff, and they 
will be provided with appropriate numbers to contact if they 
have any questions subsequently. If the participant or repre-
sentative agrees to participate, they will be asked to sign and 
date an informed consent form (Appendix 5, Extended data58). 
A copy of the form will be given to them to keep. If required, 
the participant or representative will be given up to 24 hours to 
consider the study provided the participant remains eligible 
for the study.
Participants who were consented by a representative will 
be approached to consider consent independently if at any 
time during study participation s/he becomes able to consider 
consent independently. 
In addition to the procedures above, illiterate signatories 
will have the informed consent form read to them in the pres-
ence of a witness who will sign to confirm that the form was read 
accurately and that the participant or representative agrees to 
participation. All patient information sheets and Consent/ 
Assent forms will be written in the local language and will 
use terms that are easily understandable. Clinical care will 
not be delayed in any case during consideration of consent.
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Risks
This study will use a drug that has been studied thoroughly and 
its toxicities are well described. Further details can be found 
in the Study Treatment section of this protocol. While QT 
prolongation is described for Tamoxifen, life threatening arrhyth-
mias have not been. QT prolongation has also been described 
for fluconazole. Polymorphic ventricular tachycardia has been 
described in association with fluconazole use, but this is an 
extremely rare event. It is not clear if combining Tamoxifen with 
fluconazole will increase the risk of prolonged QT interval and 
TdP. Less than 20% of cases of TdP will progress to ventricular 
fibrillation. The possible risk of TdP must be considered in the 
context of the risk of death of approximately 50% for patients 
with cryptococcal meningitis. Patients will be closely monitored 
for all adverse events and treated as per standard of care. Addi-
tional volumes of blood and cerebral spinal fluid will be taken for 
research tests. These volumes have very little risk of affecting 
the participant’s health. Some phlebotomy may be performed 
more often than is required by clinical care. This procedure 
carries the small risk of bruising and infection.
Tamoxifen and fluconazole may be teratogenic and Tamoxifen 
is present in breast milk. Therefore pregnant and breast-feeding 
women are excluded from this trial, and will be counselled 
to use contraception until 3 months after the study end.
Benefits
It is unknown if study participants who receive study treat-
ment will benefit. The additional monitoring and follow-up of 
patients by dedicated study staff may be of benefit to patients 
treated in resource limited settings. For the duration of the study 
all treatment costs associated with cryptococcal meningitis 
will be met including antifungal therapy, lumbar puncture, and 
study investigations. The study will pay for anti-arrhythmic 
drugs if needed, ECGs, and review by a cardiologist if clini-
cally indicated. Training in laboratory and clinical procedures, 
research methods and good clinical practice, will be given 
to all participating centres. Investigators will engage with the 
HIV/AIDS community in each setting to ensure that trial conduct 
is cohesive with local patient support services. 
Alternatives to Study Participation
The alternative to participation in this study is routine care 
by the doctors in the hospital. Patients will be responsible for 
their own treatment costs as per local norms and hospital policy.
Confidentiality
Participants will be assured that all information generated in 
this study will remain confidential. The trial staff will ensure 
that the participants’ anonymity is maintained. Participant’s 
names will be recorded at the time of enrolment to allow for their 
identification at follow-up visits. However identifiable informa-
tion will be linked to stored data or samples only by a protected 
Master List. This list will not be shared outside the study staff. 
All documents will be stored securely and all reports or sam-
ples will be coded without identifying information. Direct access 
will be granted to authorized representatives from the host 
institution and the regulatory authorities, if applicable, to permit 
trial-related monitoring and inspections. 
Withdrawal of participants from the study
Each participant has the right to withdraw from the study 
at any time. All patients who withdraw will be referred for 
treatment as per routine clinical care. The reason for withdrawal 
will be recorded in the CRF.
Sample sharing and storage
Samples collected will be used for the purpose of this study 
as stated in the protocol and stored for future use in studies 
not yet conceived, which may include genetic studies. Con-
sent will be obtained from subjects for genetic testing and for 
sample storage and/or shipment of specific samples to collabo-
rating institutions for investigations that cannot be performed 
locally. Any proposed plans to use samples other than for those 
investigations detailed in this protocol will be submitted to 
the relevant ethics committees prior to any testing.
The participants will be identified only by a study specific 
participant number and/or code in any database. The name and 
any other identifying detail will NOT be included in any study 
data electronic file.
Sponsorship and Insurance
The University of Oxford has appropriate insurance-related 
arrangements in place in respect of the University’s role as 
research sponsor for this study (Contact: University of Oxford, 
Research Services, University Offices, Wellington Square, 
Oxford OX1 2JD, Tel +44 (0) 1865 282585).
Trial Registration
The trial was registered at ClinicalTrials.gov ID: NCT03112031 on 
the 13 April 2017
Data
Data collection and entry
Source documents will be generated during the study by the 
site study staff at participating institutions. Source documents 
include all original recordings of observations or notations of 
clinical activities, and all reports and records necessary for the 
evaluation and reconstruction of the clinical trial. Source docu-
ments include, but are not limited to, the subject’s medical records, 
research case record forms (paper or electronic), laboratory 
reports, ECG tracings, x-rays, radiologist’s reports, subject’s 
diaries and questionnaires, biopsy reports, ultrasound photo-
graphs, progress notes, pharmacy records, and any other similar 
reports or records of procedures performed during the subject’s 
participation in the study.
Access to applicable source documents is required for study 
purposes. The site investigators are responsible for maintain-
ing any source documentation related to the study. Source 
documentation should support the data collected on the 
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CRF when the CRF is not the original site of recording. Source 
documentation must be available for review or audit by the 
sponsor or designee and any applicable regulatory authorities.
Case Report Forms (CRFs) will be used as a data collection 
tool. The study team will transfer the information from the 
source documents onto the CRFs. CRFs may be used as source 
documents if they are the primary data collection tool for 
specified data as documented in written standard operating 
procedures. The site Investigators are responsible for maintain-
ing accurate, complete and up-to-date records. These forms 
are to be completed on an ongoing basis during the course 
of the study by authorized individuals.
Corrections to paper CRFs must be initialed and dated by the 
person making the correction and must not obliterate the original 
entry. All CRFs should be reviewed by the designated study staff 
and signed as required with written or electronic signature, as 
appropriate.
Selected study members (study doctors or nurses) will be 
trained on how to enter all clinical data as source information 
from the CRFs and from laboratory source documents into an 
internet-based computerized data entry system called CliRes 
hosted by OUCRU Viet Nam. Data entry will occur simulta-
neously as data are being generated during the trial as soon as 
possible after the information is generated. Data may 
be manually entered or scanned and electronically uploaded 
dependent on available software. Source documents and 
electronic data will be verified according to the Trial Monitoring 
Plan.
Following study completion and the main analyses and pub-
lication of the study results, the study sub-datasets consisting 
of the patient data from particular recruiting sites will be 
available to the investigators from those sites.
Record Retention
The trial will be conducted to Good Clinical Practice (GCP) 
in line with the UK medical Research Council guidelines. The 
investigator is responsible for retaining all essential docu-
ments as listed in the MRC guidelines on GCP. All essential 
documentation for all study subjects are to be maintained in 
original paper format by the investigators in a secure storage 
facility for a minimum of 3 years and as required by local 
regulations thereafter. All essential documentation will be 
converted from paper to electronic format (if required) and 
stored centrally for at least 10 years after the completion of the 
trial and as required by local regulations thereafter. 
All stored records are to be kept secure and confidential.
Monitoring
The trial will be conducted in compliance with this protocol, 
Medical Research Council Guidelines of Good Clinical Practice 
and any applicable regulatory requirement(s). 
The study will be adequately monitored by the OUCRU or 
their designate. Monitors will visit the clinical research site to 
monitor all aspects of the study in accordance with the appro-
priate regulations and the approved protocol. The objectives 
of a monitoring visit will be: 1) to verify the existence of ade-
quately signed informed consent documents for each enrolled 
subject; 2) to verify the prompt, complete and accurate record-
ing of all monitored data points, and prompt reporting of all 
SAEs and unexpected SAEs; 3) to compare abstracted infor-
mation with individual subjects’ records and source documents 
(subjects’ charts, case report forms, laboratory analyses and test 
results, physicians’ progress notes, nurses’ notes, and any other 
relevant original subject information); 4) to verify the supply 
and condition of the study drug and the accurate and 
secure assignment of randomization code; and 5) to ensure 
protection of study subjects, investigators’ compliance with 
the protocol, and completeness and accuracy of study records. 
The monitors also will inspect the clinical site regulatory files 
to ensure that regulatory requirements and applicable guidelines 
are being followed. During the monitoring visits, the investiga-
tor (and/or designee) and other study personnel will be available 
to discuss the study progress and monitoring visit.
Dissemination of findings
Results of the study will be published in international peer 
reviewed journals, presented at national and international 
conference, and publicized on the OUCRU website and through 
OUCRU social media accounts. Any publication or presenta-
tion during the active phase of the study must have permission 
from the Investigators. The investigators will define the strat-
egy for publication, resolve any problems of authorship and 
maintain the quality of publications. All publications will acknowl-
edge the appropriate authors and funding sources according 
to normal academic practice. The investigators are the custodian 
of the data and specimens generated from this trial.
Trial status
The trial started recruiting patients in November 2017 and 
finished enrollment in May 2018. Data analysis is on-going.
Discussion
Current best treatment for cryptococcal meningitis, consisting 
of amphotericin combined with flucytosine for the initial two 
weeks of treatment, is life-saving but remains associated with 
unacceptably high death rates in the order of 30–40%. 
Moreover, flucytosine, while an old drug that is off–patent, 
remains poorly available and extremely expensive. Its high cost 
(10–15,000 USD per week in the USA) illustrates that narrow 
spectrum, Cryptococcus-specific drugs are never likely to be 
a solution for the vast majority of patients, because there are no 
economies of scale in either drug development or manufacture. For 
this reason, the repurposing of off-patent drugs that have fre-
quent indications for common, unrelated conditions, holds the 
main hope of improving outcomes from this devastating disease. 
Tamoxifen fits this profile perfectly. This controlled trial will 
deliver initial efficacy and safety data to enable the field to 
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determine whether tamoxifen should be trialed in a larger study 
powered to mortality. If successful, tamoxifen has the potential 
to transform care of cryptococcal disease since it is cheap, has 
stable costs driven by a common alternate diagnosis (breast 
cancer), and is widely available. 
Data availability
Underlying data
All data underlying the results are available as part of the article 
and no additional source data are required
Extended data
Additional information regarding the protocol is available 
as Extended data from the Oxford University Research 
Archive (ORA).
The document contain the following –
Appendix 1 - Management of raised intracranial pressure
Appendix 2 - Amphotericin administration and complications
Appendix 3 - Presumptive and definitive criteria for AIDS defining 
events
Appendix 4 - Drugs associated with prolonged QTc and TdP 
which must not be coadministered with Tamoxifen during the 
first 2 weeks of this study.
Appendix 5 - Patient Information sheet and Informed Consent 
Form
ORA: Extended data. Extended data - Appendices - A 
randomised controlled trial of tamoxifen for cryptococcal 
meningitis. https://doi.org/10.5287/bodleian:NG5DwvJDN58
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Thoughts:
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This is a straightforward and very well written protocol that examines the potential benefit of adding
tamoxifen to amphotericin B and fluconazole for cryptococcal meningitis, using as an end-point the early
fungicidal activity of the combination therapy. The primary outcome has been well accepted as an early
indicator of clinical efficacy and has correlated with clinical outcomes in other trials,
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Ngan and colleagues have presented a well-written and detailed protocol of a phase II, open-label,
randomized controlled trial designed to evaluate initial efficacy and safety data for adjunctive tamoxifen
added to standard antifungal therapy for cryptococcal meningitis. As the authors point out, the most
effective treatment combination with amphotericin and flucytosine remains unavailable in much of the
world where the burden of cryptococcal meningitis is the greatest. As such, the identification of a novel
drug effective against   would represent an important advance. Given the inherentCryptococcus
challenges involved in   antifungal development, drug repurposing is an attractive approach forde novo
new antifungal discovery.
This experienced research group should be commended for advancing tamoxifen, a widely accessible
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 This experienced research group should be commended for advancing tamoxifen, a widely accessible
SERM used in breast cancer, into clinical trial status for cryptococcal meningitis. In pre-clinical studies,
tamoxifen has demonstrated fungicidal activity against   when combined with fluconazoleCryptococcus
and appears synergistic with amphotericin. In this protocol, the authors outline a well-designed
randomized study in Vietnam comparing standard induction therapy (amphotericin + fluconazole) to
standard induction therapy with the addition of tamoxifen 300mg daily.  The primary outcome is EFA.
Secondary outcomes include 10-week survival and disability, grade ≥3 AEs including QT prolongation
and visual deficits, rates of paradoxical IRIS and relapse, changes in intracranial pressure and CD4 count,
and concentrations of tamoxifen and fluconazole in blood and CSF. The goal of the study is to inform the
decision to proceed to a phase III trial powered for mortality, which is planned if adjunctive tamoxifen is
found to improve CSF fungal clearance.
I have no specific amendments suggested to this publication, but would offer the following comments as
the authors move forward through the study process:
Background and Rationale: Well-reasoned with appropriate background provided, including rationale of
tamoxifen as antifungal, existing pre-clinical data, pharmacology and adverse effects.  My only comment
would be regarding headings (might be more of a publication error).  Adverse events should be bolded,
while subsequent subsections should not.
Regarding EFA as a primary endpoint: have the authors considered the possibility of an “efficacy ceiling”
for EFA that masks any potential activity of tamoxifen when it comes fungal clearance? For example,
fluconazole is effective for cryptococcosis outside the induction period (consolidation, maintenance,
asymptomatic CrAg antigenemia), though no mortality benefit has ever been convincingly demonstrated
for fluconazole as part of combination induction therapy. In other words, demonstrating efficacy of
tamoxifen in this study might be difficult using EFA as primary endpoint given presence of potent regimen
containing amphotericin. If no improvement in EFA is observed during this trial, would the idea of
tamoxifen as treatment for  be abandoned? Perhaps there would still be room for evaluatingCryptococcus 
outcomes outside of the induction period?
Statistics: again on the topic of EFA…  I would agree with the authors decision to determine EFA based
on a linear mixed-effects model including all LP timepoint collected, as this would provide the most
accurate and sensitive EFA for purposes of comparison between the two study groups. However, have
the authors considered including other methods of calculating EFA as well?  It may be helpful in the final
analysis to also include general linear regression models and to include models that limit the LP
timepoints used in calculations to day 1, 7, and 14. This would be useful in comparing EFA across other
studies, and bring attention to the fact that standardization of EFA across cryptococcal meningitis studies
needs to be prioritized.
Trial status: I am excited to see the results of this study!  Just curious why the authors submitted the
protocol for publication only after enrollment into the study has concluded?
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Many thanks for the thoughtful comments. Were agree, particularly within the light of the recently
published ACTA trial, that it is possible that a drug may have mortality benefits that are not
necessarily detectable through measurement of EFA. However, in general, increased rates of EFA
are strongly associated at the population level with improvements in survival. Particularly, the
combination of amphotericin with flucytosine, which appears synergistic   for the majorityin vitro
(~80%) of clinical isolates (as we found for tamoxifen and amphotericin), delivers the steepest
declines in CSF fungal load, so EFA seemed an appropriate endpoint for this combination at this
juncture.  This this will be the first use of tamoxifen within humans with cryptococcal disease - we
felt it imperative to generate these efficacy and safety data prior to any trial powered to mortality.
However, all patients will be followed until 10 weeks after randomisation, although we will lack
power to demonstrate and effect with this sample size.
Publication of the protocol after the commencement of study enrolment represents unfortunate
inefficiency on the part of the PI. The protocol was or course peer reviewed prior to ethical
submissions and funding. 
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